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INTRODUCTION {#gcc22347-sec-0001}
============

Pheochromocytomas (PCCs) and abdominal paragangliomas (PGLs), together abbreviated PPGL, are neuroendocrine tumors of the adrenal medulla and extra‐adrenal paraganglia, respectively, displaying a highly heterogeneous genetic background (Dahia, [2014](#gcc22347-bib-0012){ref-type="ref"}). Although the majority of cases are benign, significant subsets of PGLs are malignant and often associated with inactivating *SDHB* gene mutations. Recent studies have revealed that approximately 40% of PPGL patients carry a constitutional mutation in a susceptibility gene, and somatic mutations are found in an additional 30% of the tumors (Dahia, [2014](#gcc22347-bib-0012){ref-type="ref"}). The currently known susceptibility genes include *NF1*, *RET*, *VHL, SDHA*, *SDHB*, *SDHC*, *SDHD*, *SDHAF2*, *EGLN1, EPAS1, FH* (Letouzé et al., [2013](#gcc22347-bib-0018){ref-type="ref"})*, KIF1Bb* (Schlisio et al., [2008](#gcc22347-bib-0023){ref-type="ref"})*, MAX* (Comino‐Méndez et al., [2011](#gcc22347-bib-0009){ref-type="ref"}), and *TMEM127* (Dahia, [2014](#gcc22347-bib-0012){ref-type="ref"}). Single families with PPGL and a constitutional mutation in one of the genes *BAP1* (Wadt et al., [2012](#gcc22347-bib-0025){ref-type="ref"}) and *MDH2* (Cascón et al., [2015](#gcc22347-bib-0007){ref-type="ref"}) have also been reported. The known genetic background of PPGL further includes a set of genes that are recurrently mutated in PPGL tumors such as *ATRX* (Fishbein et al., [2015](#gcc22347-bib-0016){ref-type="ref"})*, KMT2D* (Juhlin et al., [2015](#gcc22347-bib-0017){ref-type="ref"})*, MET* (Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"})*, BRAF* (Luchetti et al., [2015](#gcc22347-bib-0020){ref-type="ref"}), the *TERT* promoter (Liu et al., [2014](#gcc22347-bib-0019){ref-type="ref"}), and *HRAS* (Yoshimoto et al., [1992](#gcc22347-bib-0029){ref-type="ref"}; Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}). Expressional profiling studies of PPGL have shown that tumors fall into two main clusters depending on their genetic composition (Dahia et al., [2005](#gcc22347-bib-0013){ref-type="ref"}; Burnichon et al., [2011](#gcc22347-bib-0006){ref-type="ref"}). Cluster 1 with *VHL*, *SDHx* and *EPAS1* mutated tumors is characterized by a pseudo‐hypoxic response and Cluster 2 includes tumors with mutations in *MAX, NF1, RET*, and *TMEM127* that are associated with active kinase‐signaling pathways (Dahia et al., [2005](#gcc22347-bib-0013){ref-type="ref"}).

Somatic mutations in the *Harvey rat sarcoma viral oncogene homolog (HRAS)* gene were first reported in a single pheochromocytoma (Yoshimoto et al., [1992](#gcc22347-bib-0029){ref-type="ref"}), and *HRAS* was more recently verified as a recurrently mutated gene in PCC. However, the two other members of the RAS family, that is, *NRAS* and *KRAS* have not been reported to be mutated in PPGL. Crona et al. identified *HRAS* mutations via exome sequencing and reported 3 mutated PCCs and 1 PGL (Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}). Oudijk and co‐workers subsequently detected *HRAS* mutations in 5.2% of cases (14/271 PCCs) and proposed that the mutations are restricted to sporadic PCCs (10%, 14/140) (Oudijk et al., [2014](#gcc22347-bib-0022){ref-type="ref"}) and Luchetti et al. published *HRAS* mutations in 6/65 PPGL (9.2%) (Luchetti et al., [2015](#gcc22347-bib-0020){ref-type="ref"}). Recently, in a multiomics study by Castro‐Vega et al. the authors screened 193 PPGL for *HRAS* mutations and found 10 mutated cases, all in benign, sporadic PPGL (Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"}). Additionally, de Cubas et al. have mentioned 4 *HRAS*‐mutated PPGL among 156 cases screened, whereof one mutation was found in a metastatic PPGL (de Cubas et al., [2015](#gcc22347-bib-0011){ref-type="ref"}). Mutations at the hotspots codons 13 and 61 activate the transforming properties of various tumor types, and hence these recurrent mutations are thought to propagate PPGL tumorigenesis for a subset of cases. Germ‐line *HRAS* mutations have been associated with the Costello syndrome, but to date no co‐occurrence of this syndrome and PPGL has been reported (Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}; Luchetti et al., [2015](#gcc22347-bib-0020){ref-type="ref"}). In this study, we aimed to further establish the *HRAS* mutation prevalence as well as its possible impact on global mRNA expression profiles in *HRAS* mutated PPGL.

MATERIALS AND METHODS {#gcc22347-sec-0002}
=====================

Pheochromocytoma and Paraganglioma (PPGL) Tumor Samples {#gcc22347-sec-0003}
-------------------------------------------------------

A total of 156 PPGL (142 PCCs and 14 PGLs) were collected from Karolinska University Hospital, Stockholm, Sweden (Series A; *n* = 75), University de Lorraine, Vandoeuvre‐les‐Nancy, France (Series B, *n* = 60), Linköping University Hospital, Sweden (Series C, *n* = 12), and Haukeland University Hospital in Bergen, Norway (Series D, *n* = 9), (Supporting Information Table 1). Samples were obtained with informed patient consent and with approval from the local ethics committee of the respective centers. Tumors were classified as benign or malignant following the WHO criteria (DeLellis et al., [2004](#gcc22347-bib-0014){ref-type="ref"}). For Series A, a subset of the tumors (*n* = 54) had been characterized for mutations in 14 proposed PPGL susceptibility genes (*EGLN1, EPAS1 KIF1Bβ, MAX, MEN1, NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127*, and *VHL*) (Welander et al., [2014a](#gcc22347-bib-0027){ref-type="ref"}) and the remaining tumors (*n* = 21) were screened for mutations in 8 of these genes (*EPAS1, MAX, NF1, SDHB, SDHD, RET, TMEM127*, and *VHL*) (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}) (Supporting Information Table 1). Furthermore, all tumors in Series C and D were previously analyzed for mutations in the 8 genes (*EPAS1, MAX, NF1, SDHB, SDHD, RET, TMEM127*, and *VHL*) (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}) (Supporting Information Table 1). For Series B, a subset of patients exhibited established PPGL syndromes with associated mutations (Supporting Information Table 1).

*HRAS* Mutation Analysis {#gcc22347-sec-0004}
------------------------

Genomic DNA isolated from fresh frozen tumor samples was used for amplification of fragments of exon 2 and 3 covering codons 13 and 61 of the *HRAS* gene (NM_001130442) with primer sequences available upon request. Sanger sequencing was carried out at the KIGene core facility at Karolinska Institutet for 113 cases and at Linköping University for 42 cases using previously described methodology (Welander et al., [2014a](#gcc22347-bib-0027){ref-type="ref"}). All samples showing chromatogram alterations were re‐analyzed with the reverse primer. One *HRAS* mutation (case 88) has been previously reported and was found via whole‐exome sequencing (Supporting Information Table 1) (Juhlin et al., [2015](#gcc22347-bib-0017){ref-type="ref"}).

Gene Expression Profiling {#gcc22347-sec-0005}
-------------------------

Total RNA was extracted from 53 PPGLs from Series A (Supporting Information Table 1), using the mirVana Isolation Kit (Ambion, Austin, TX) and subsequently analyzed in an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). As previously reported, RNA preparations from all cases were of sufficient quality as measured by RIN values (Andreasson et al., [2013a](#gcc22347-bib-0002){ref-type="ref"}, [2013b](#gcc22347-bib-0003){ref-type="ref"}). RNA samples (250 ng) were used for whole‐transcriptome analysis with GeneChip Human Gene 1.0 ST arrays (Affymetrix), covering approximately 29K annotated genes as previously described (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}). Tumor RNA from 40 cases in Series A--C (detailed in Supporting Information Table 1) had previously been analyzed with the GeneChip Human 1.0 ST array (Affymetrix) (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}). *HRAS* mutation status from the current study was implemented into the dataset and after normalization using the robust multiarray average (RMA) algorithm, hierarchical clustering of the microarray expression data for all 93 PPGLs was performed as previously described (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}) using a set of genes that has been shown to separate the clusters (Burnichon et al., [2011](#gcc22347-bib-0006){ref-type="ref"}). These genes overlapped with 454 of the probe sets in our analysis which were used to perform the hierarchical clustering. Moreover, gene expression profiles based on the entire probe sets on the array were compared between the 7 *HRAS* mutated cases and the 91 *HRAS* wild‐type cases included. Given their involvement in PPGL, normalized signal intensities for the *HRAS*, *vascular endothelial growth factor A* (*VEGFA*) and *phenylethanolamine N‐methyltransferase* (*PNMT*) genes were exported for separate statistical analysis.

Within the cohort, tumors with known somatic mutations in *EPAS1, KIF1Bb, MAX, NF1, RET, SDHA, SDHB, TMEM127*, and *VHL* were included (Supporting Information Table 1). Additionally, five cases from patients with known PPGL syndromes (2 MEN2, 1 NF1, 1 PGL5, and 1 VHL) were included as internal controls and were also included in the hierarchical clustering. One identical sample was analyzed at both time points in (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}) and in the current study as an internal control between the GeneChip arrays. This sample did not show any difference in clustering behavior as evaluated with a principal component analysis quality control in the GeneSpring software (data not shown).

Statistical Analyses {#gcc22347-sec-0006}
--------------------

Transcriptome‐wide statistical analyses and clustering were performed as previously described (Welander et al., [2014b](#gcc22347-bib-0028){ref-type="ref"}) using the GeneSpring GX v. 12.6 (Agilent, Santa Clara, CA) software and the Benjamini--Hochberg method (Benjamini and Hochberg, [1995](#gcc22347-bib-0005){ref-type="ref"}) was used to control for multiple testing. When comparing the gene expression profiles between the 7 *HRAS* mutated cases and the 91 *HRAS* wild‐type cases based on the entire probe sets on the array, a Benjamini--Hochberg corrected false discovery rate (FDR) of less than 0.1 was applied. Gene expression levels for *HRAS*, *VEGFA*, and *PNMT* were compared between sporadic *HRAS‐*mutated and *HRAS* wild‐type tumors using two‐tailed Student\'s *t‐*test. Two‐tailed Mann--Whitney *U* or Fisher\'s exact tests were used to analyze potential significant correlations between the clinical parameters and *HRAS* mutational status. *P*‐values of less than 0.05 were considered as statistically significant.

RESULTS {#gcc22347-sec-0007}
=======

Detection of *HRAS* Mutations {#gcc22347-sec-0008}
-----------------------------

A *HRAS* mutation was found in 11 out of 156 tumors screened (142 PCCs and 14 PGLs), equaling a total frequency of 7.1% (11/156) in our cohort (Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}). One mutation was found in exon 2 (G13R) and ten mutations were found in exon 3 (six Q61R, three Q61K, and one Q61L) (Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}, Fig. [1](#gcc22347-fig-0001){ref-type="fig"}A).

![Detection of a *HRAS* Q61L mutation, hierarchical clustering of PPGLs and *PNMT* gene expression in relation to *HRAS* mutation status. **(A)** Chromatogram of case 227 (PGL) showing the Q61L mutation (c.182A\>T, COSM498), which has previously not been reported in PPGL. A vertical arrow shows the heterozygous missense variant. **(B)** Hierarchical clustering of 93 tumors (indicated by their case numbers) and 5 control cases (indicated as MEN2, NF1, SDHA, and VHL) based on their expression levels for 454 genes according to Burnichon et al. [2011](#gcc22347-bib-0006){ref-type="ref"}. The dendrogram shows separation of tumors into two distinct groups (Cluster 1 to the left and Cluster 2 to the right). The PPGL mutation status is indicated below. All 7 *HRAS‐*mutated cases clustered together with the tumors endowed with mutations in the *NF1‐* and *RET* genes. **(C)** RNA levels of the *PNMT* gene compared between the PPGL with (*HRAS* mutated *n* = 7) and without (*HRAS* wild‐type *n* = 86) *HRAS* mutations. Horizontal bars represent mean values and the gene expression has been normalized to the mean value of cases endowed with constitutional *NF1‐* and *RET* mutations. \[Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).\]](GCC-55-452-g001){#gcc22347-fig-0001}

###### 

*HRAS* Gene Mutations and Clinical Characteristics of the PPGL Included in the Study

                                              Series         Series         Series        Series        Series
  ------------------------------------------- -------------- -------------- ------------- ------------- ----------------
  **Gender**                                                                                            
  Male:Female                                 32:43          26:34          5:7           3:6           66:90
  **Age at diagnosis**                                                                                  
  Mean years                                  55             53             63            58            55
  Median (range) years                        57 (14--83)    52 (23--84)    66 (39--76)   58 (42--80)   57 (14--84)
  **Tumor type**                                                                                        
  Total                                       75             60             12            9             156
  PCC                                         64             57             12            9             142
  PGL                                         11             3              0             0             14
  **Tumor size**                                                                                        
  Mean mm                                     52             41             34            47            46
  Median (range) mm                           45 (20--160)   40 (10--100)   30 (17--60)   50 (10--90)   40 (10--160)
  **Malignancy**                                                                                        
  Benign                                      69             59             12            9             149
  Malignant                                   6              1              0             0             7
  **PPGL susceptibility gene**                                                                          
  Mutated                                     37             9              3             6             55
  Unknown mutation (sporadic)                 38             51             9             3             101
  ***HRAS* codon 13 and 61**                                                                            
  Wild‐type                                   70             57             10            8             145
  Mutated                                     5              3              2             1             11
  G13R                                        0              0              1             0             1
  Q61R                                        3              1              1             1             6
  Q61K                                        2              1              0             0             3
  Q61L                                        0              1 (PGL)        0             0             1
  ***HRAS* mutation frequencie*s***                                                                     
  Total                                       6.7%           5.0%           16.7%         11.1%         11/156 (7.1%)
  PCC                                         7.8%           1.5%           16.7%         11.1%         10/142 (7.0%)
  PGL                                         0%             33.3%          0%            0%            1/14 (7.1%)
  *According to gender*                                                                                 
  Male                                        6.3%           7.7%           0%            0%            4/66 (6.1%)
  Female                                      7.0%           2.9%           28.6%         16.7%         7/90 (7.8%)
  *According to malignancy*                                                                             
  benign                                      7.2%           5.1%           16.7%         11.1%         11/149 (7.4%)
  Malignant                                   0%             0%             0%            0%            0/7 (0%)
  *According to susceptibility gene status*                                                             
  Unknown mutation (sporadic)                 13.2%          5.9%           22.2%         33.3%         11/101 (10.9%)
  Mutated                                     0%             0%             0%            0%            0/55 (0%)

Tumor size refer to the maximum diameter.

Series A = Karolinska University Hospital, Sweden.

Series B = University de Lorraine, Vandoeuvre‐les‐Nancy, France.

Series C = Linköping University Hospital, Linköping, Sweden.

Series D = Haukeland University Hospital, Bergen, Norway.

The *HRAS* mutation frequency in apparently sporadic PPGL (non‐familial and without known susceptibility gene mutation) was 10.9% (11/101; Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}). The *HRAS* mutation status was compared with clinical and genetic characteristics of the present cohort and in combination with published studies (Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}). No *HRAS* mutation was found in any PPGL endowed with a known PPGL susceptibility gene mutation (Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}, Supporting Information Table 1). Hence, *HRAS* mutations were associated with the PPGL group without a known susceptibility gene mutation both in our study (Fisher\'s exact test, *P* = 0.017) (Table [1](#gcc22347-tbl-0001){ref-type="table-wrap"}) and in all available studies combined (Fisher\'s exact test, *P* \< 0.0001) (Table [2](#gcc22347-tbl-0002){ref-type="table-wrap"}). Regarding clinical parameters, no mutations were found in PPGLs classified as malignant according to the current WHO criteria and the patients endowed with a *HRAS* mutation tended to have higher age at diagnosis (mean 63 ±10 years) compared with those without *HRAS* mutation (mean 54 ±16 years) however this association did not reach statistical significance (two‐tailed Mann--Whitney *U*‐test, *P* = 0.08). In our series of 11 mutated PPGLs there were four men and seven women, and no gender‐related difference in *HRAS* mutation frequency was observed (Fisher\'s exact test, *P* = 0.76). The mean tumor sizes of *HRAS‐*mutated and wild‐type cases were 58 ± 41 mm and 45 ± 22 mm, respectively. This difference was not statistically significant (Two‐tailed Mann--Whitney *U*‐test, *P =* 0.37).

###### 

Summary of *HRAS* Mutation Studies in PPGL

                                                                                                                       *HRAS* gene status   PPGL susceptibility gene                                                                                      
  -------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------- --------------- -------------- -------------- ----------------- ------------------ -------------------
  ***This study*** [a](#gcc22347-note-0007){ref-type="fn"}                                                                                                                                                                                                
  PCC (*n =* 141)                                                                                                      9                    1                          5               3              0              132               48                 93
  PGL (*n =* 14)                                                                                                       1                    0                          0               0              1              13                7                  7
  Total (*n =* 155)                                                                                                    10                   1                          5               3              1              145               55                 100
  ***Moley et al.*** [***1991***](#gcc22347-bib-0030){ref-type="ref"}                                                                                                                                                                                     
  PCC (*n =* 10)                                                                                                       0                    0                          0               0              0              10                0                  10
  Total (*n =* 10)                                                                                                     0                    0                          0               0              0              10                0                  10
  ***Yoshimoto et al.*** [***1992***](#gcc22347-bib-0029){ref-type="ref"}                                                                                                                                                                                 
  PCC (*n =* 19)                                                                                                       1                    1                          0               0              0              18                0                  19
  Total (*n =* 19)                                                                                                     1                    1                          0               0              0              18                0                  19
  ***Crona et al.*** [***2013***](#gcc22347-bib-0010){ref-type="ref"}, [b](#gcc22347-note-0008){ref-type="fn"}                                                                                                                                            
  PCC (*n =* 72)                                                                                                       3                    1                          1               1              0              69                22                 50
  PGL (*n =* 9)                                                                                                        1                    0                          1               0              0              8                 3                  6
  Total (*n =* 81)                                                                                                     4                    1                          2               1              0              77                25                 56
  ***Oudijk et al. 2013***                                                                                                                                                                                                                                
  PCC (*n =* 216)                                                                                                      14                   1                          12              1              0              202               76                 140
  PGL (*n =* 55)                                                                                                       0                    0                          0               0              0              55                31                 24
  Total (*n =* 271)                                                                                                    14                   1                          12              1              0              257               107                164
  ***Luchetti et al.*** [***2015***](#gcc22347-bib-0020){ref-type="ref"}, [c](#gcc22347-note-0010){ref-type="fn"}                                                                                                                                         
  PCC (*n =* 60)                                                                                                       6                    1                          5               0              0              54                16                 44
  PGL (*n =* 5)                                                                                                        0                    0                          0               0              0              5                 0                  5
  Total (*n =* 65)                                                                                                     6                    1                          5               0              0              59                16                 49
  ***Castro‐Vega et al.*** [***2015***](#gcc22347-bib-0008){ref-type="ref"}, [d](#gcc22347-note-0009){ref-type="fn"}                                                                                                                                      
  PCC (*n =* 168)                                                                                                      10                   1                          4               2              0              158               100                68
  PGL (*n =* 25)                                                                                                       0                    0                          0               0              0              25                16                 9
  Total (*n =* 193)                                                                                                    10                   1                          4               2              0              183               116                77
  ***de Cubas et al.*** [***2015***](#gcc22347-bib-0011){ref-type="ref"}                                                                                                                                                                                  
  PCC (*n =* 128)                                                                                                      3                    0                          3               0              0              125               68                 60
  PGL (*n =* 28)                                                                                                       1                    0                          0               1              0              27                15                 13
  Total (*n =* 156)                                                                                                    4                    0                          3               1              0              152               83                 73
  ***HRAS mutations in the eight studies***                                                                                                                                                                                                               
  *  *PCC (*n =* 814)                                                                                                  **46 (5.7%)**        6 (0.7%)                   30 (3.7%)       7 (0.9%)       0              768 (94.3%)       1/330 (0.3%)       45/484 (9.3%)
  *  *PGL (*n =* 136)                                                                                                  **3 (2.2%)**         0                          1 (0.7%)        1 (0.7%)       1 (0.7%)       133 (97.8%)       0/72               3/64 (4.7%)
  Total (*n =* 950)                                                                                                    **49 (5.2%)**        **6 (0.6%)**               **31 (3.3%)**   **8 (0.8%)**   **1 (0.1%)**   **901 (94.8%)**   **1/402 (0.2%)**   **48/548 (8.8%)**

One PCC with a Q61R *HRAS* mutation has been previously published (Juhlin et al., [2015](#gcc22347-bib-0017){ref-type="ref"}) and is excluded.

One head and neck paraganglioma is excluded.

Twenty head and neck paragangliomas are excluded.

Six metastases and 3 thoracic paragangliomas are excluded. Three *HRAS* mutations from this study are not reported in the table: G12R (*n* = 1), S145L (*n* = 1), and A146T (*n* = 1).

mRNA Expression Profiles of *HRAS* Mutated PPGLs {#gcc22347-sec-0009}
------------------------------------------------

Two approaches were taken to reveal gene expression profiles associated with the *HRAS* mutational status. First, hierarchical clustering was performed using the previously defined set of 454 probe sets (Burnichon et al., [2011](#gcc22347-bib-0006){ref-type="ref"}). This showed that the seven *HRAS* mutated PPGL clustered together with the tumors endowed with mutations in the *NF1* and *RET* genes, associated with PIK3/AKT/mTOR and RAS/RAF activation in Cluster 2 (Fig. [1](#gcc22347-fig-0001){ref-type="fig"}B). When *HRAS* mutated and *HRAS* wild‐type cases were separately compared for the individual genes *HRAS*, *VEGFA*, and *PNMT*, the latter was found to have significantly higher expression in *HRAS‐*mutated cases (Student\'s *t*‐test, *P* = 0.018) (Fig. [1](#gcc22347-fig-0001){ref-type="fig"}C) whereas *HRAS* and *VEGFA* did not show statistically significant differences between groups (Student\'s *t*‐test, *P* = 0.061 and *P* = 0.29, respectively).

Subsequently, the 7 *HRAS* mutated tumors were compared with 91 *HRAS* wild‐type tumors using the complete set of probe sets on the array. Based on this, 21 differentially expressed transcripts were identified as detailed in Table [3](#gcc22347-tbl-0003){ref-type="table-wrap"}. Thirteen of the identified transcripts correspond to a known gene, including the *receptor‐type tyrosine‐protein phosphatase zeta (PTPRZ1)* and the *transmembrane protein 195 (TMEM195)* as the two most up‐regulated genes.

###### 

Genes with Altered Expression in *HRAS* Mutated Tumors (*n* = 7) Compared with *HRAS* Wild‐Type Cases (*n* = 91) using a Benjamini--Hochberg Corrected FDR of 10 %

  Transcript cluster id                                Corrected *P*‐value   Fold change   Fold change log   Gene symbol
  ---------------------------------------------------- --------------------- ------------- ----------------- -------------
  **Up‐regulated in *HRAS* mutated vs. wild‐type**                                                           
  8135774                                              0.0632                2.7526        1.4608            *PTPRZ1*
  8138337                                              0.0000                2.3660        1.2424            *TMEM195*
  7928907                                              0.0253                2.0682        1.0484            
  8000963                                              0.0025                1.9834        0.9880            *STX1B*
  7921852                                              0.0532                1.7622        0.8174            *MPZ*
  8107518                                              0.0532                1.6164        0.6928            
  8103374                                              0.0889                1.5410        0.6239            
  8152863                                              0.0253                1.5150        0.5993            
  8156110                                              0.0253                1.5148        0.5991            
  8000757                                              0.0005                1.4531        0.5391            *DOC2A*
  8157027                                              0.0253                1.4506        0.5367            *NIPSNAP3B*
  7998053                                              0.0854                1.3622        0.4459            
  7948037                                              0.0253                1.3206        0.4012            
  7965838                                              0.0300                1.1981        0.2608            
  8040672                                              0.0832                1.1767        0.2347            *DRC1*
  **Down‐regulated in *HRAS* mutated vs. wild‐type**                                                         
  8036483                                              0.0909                −1.3839       −0.4687           *YIF1B*
  8098705                                              0.0604                −1.3403       −0.4225           *MTRF1L*
  8061542                                              0.0832                −1.3147       −0.3948           *HM13*
  7989619                                              0.0419                −1.3038       −0.3827           *PPIB*
  7983290                                              0.0253                −1.3018       −0.3805           *SERF2*
  7924230                                              0.0832                −1.2333       −0.3025           *ABHD17A*

DISCUSSION {#gcc22347-sec-0010}
==========

In this study we aimed to further establish the *HRAS* mutation frequency in PPGL and examine the impact on global expressional profiles in *HRAS* mutated tumors. We consequently screened 156 PPGLs for mutations in the *HRAS* gene and compared the results with microarray‐based gene expression profiles for 93 (60%) of the cases.

Eleven out of 156 cases were found endowed with *HRAS* mutations equaling a total frequency of 7.1%. This prevalence is in line with previously published results (Table [2](#gcc22347-tbl-0002){ref-type="table-wrap"}) (Yoshimoto et al., [1992](#gcc22347-bib-0029){ref-type="ref"}; Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}; Oudijk et al., [2014](#gcc22347-bib-0022){ref-type="ref"}; Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"}; Luchetti et al., [2015](#gcc22347-bib-0020){ref-type="ref"}). One single mutation was found in exon 2 (G13R) and ten mutations were found in exon 3 (six Q61R, three Q61K and one Q61L). The Q61L mutation at c.182 A\>T (COSM498), which has previously not been reported in PPGL, was the only mutation found in a PGL in our cohort. This alteration has previously been reported in cutaneous squamous cell carcinoma (Su et al., [2012](#gcc22347-bib-0024){ref-type="ref"}) and in penile cancer (Andersson et al., [2008](#gcc22347-bib-0001){ref-type="ref"}).

No *HRAS* mutations were found in PPGLs classified as malignant according to the current WHO criteria, which is in line with previous findings (Yoshimoto et al., [1992](#gcc22347-bib-0029){ref-type="ref"}; Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}; Oudijk et al., [2014](#gcc22347-bib-0022){ref-type="ref"}; Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"}), however one single metastatic case with a *HRAS* mutation has been previously reported (de Cubas et al., [2015](#gcc22347-bib-0011){ref-type="ref"}). The observed male:female proportion is in line with the results shown in two studies (Oudijk et al., [2014](#gcc22347-bib-0022){ref-type="ref"}; Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"}), but conflicting the results shown in an earlier study (Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}) where 4/4 patients with *HRAS* mutations were men. The mean tumor size of *HRAS‐*mutated cases tended to be slightly increased as compared with *HRAS* wild‐type cases (58 mm vs. 45 mm), however the difference was not statistically significant which is in agreement with the results of three preceding studies where the parameter was included (Crona et al., [2013](#gcc22347-bib-0010){ref-type="ref"}; Oudijk et al., [2014](#gcc22347-bib-0022){ref-type="ref"}).

None of the *HRAS* mutated tumors in our cohort were malignant according to the WHO criteria, suggesting a role of *HRAS* mutations as a somatic driver event in benign PPGL. As with the other genes associated with kinase signaling pathways in PPGL, *HRAS* mutations appear to be associated with a benign phenotype overall, although characterization and long term follow‐up in additional cohorts will be required to determine if they may be used as predictive markers.

Activating mutations in the *HRAS* gene are known to affect MAPK signaling (Balmain and Pragnell, [1983](#gcc22347-bib-0004){ref-type="ref"}), and as might be expected, all seven *HRAS* mutated cases included in the microarray‐based profiling were grouped in Cluster 2 together with tumors harboring mutations in the *NF1, MAX, RET* and *TMEM127* genes associated with PIK3/AKT/mTOR and RAS/RAF activation. Taken together with preceding findings (Castro‐Vega et al., [2015](#gcc22347-bib-0008){ref-type="ref"}), these results support the notion that *HRAS‐*mutated cases segregate separately from Cluster 1 tumors. Tumors with *HRAS* mutations exhibited higher expression of the *PNMT* gene encoding the PNMT enzyme that catalyzes the conversion (methylation) between norepinephrine and epinephrine. This finding is in line with a previous study showing that Cluster 2 tumors have increased *PNMT* expression and hence higher epinephrine levels in the patient (Eisenhofer et al., [2004](#gcc22347-bib-0015){ref-type="ref"}). Interestingly, several tumors without mutations in any of the so far known susceptibility genes appear to form a group within Cluster 1 (Fig. [1](#gcc22347-fig-0001){ref-type="fig"}B). An underlying somatic *VHL* mutation was excluded in these cases based on previous mutation screenings in all cases included in the microarray (Supporting Information Table S1). One may speculate that these tumors might share unknown underlying genetic mechanisms that potentially involve regulation of the hypoxia response, which may be an interesting subject for future studies.

Based on the analyses using the entire probe set on the array, *PTPRZ1* was found to be the most up‐regulated gene in *HRAS* mutated PPGL compared with *HRAS* wild‐type tumors (Table [3](#gcc22347-tbl-0003){ref-type="table-wrap"}). This gene has been shown to regulate glioblastoma cell motility (Müller et al., [2003](#gcc22347-bib-0021){ref-type="ref"}) and activation of PTPRZ1 via hypoxia inducible factor‐2 alpha (HIF‐2α) has also been suggested (Wang et al., [2010](#gcc22347-bib-0026){ref-type="ref"}).

To summarize, we were able to establish a low *HRAS* mutation frequency (7.1%) in PPGL. Taken together with all other studies published up to date, the overall *HRAS* mutation prevalence in PPGL is 5.2% (49/950) and 8.8% (48/548) among apparently sporadic cases without a known PPGL susceptibility gene mutation. *HRAS* mutated cases were grouped into Cluster 2 and somatic *HRAS* mutations did not occur in patients with a known PPGL susceptibility gene mutation or in patients with malignant PPGL. Somatic *HRAS* mutations thus represent a possible driver event for a subset of benign PPGLs.
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